{"ticker": {"uuid": "092cfe2d-9146-46c4-8b42-f095a50ab572", "symbol": "ATX", "name": "Amplia Therapeutics Limited", "exchange": "ASX", "country": "AU", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Amplia Therapeutics Issues New Employee Incentive Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOdkMwY1Jva1hpVHZuTGlJZjhxemg1SkpvazhpWWpNei0yVHl2V09GMzFJUVEyNVBIVFZiQ2VoMV91MHhrclNHTTBTdkhmczBlaGNtbnhWclRNdWVOS3A2bzJ6eS1NX3J0ZGxtR0hxa3gzQW9SbDFyU3lSWFdZUFNmSWlvR04wNkJtSTJqNzgtU2d1YkNibTlSbnNUeGVEc0kyVFBhS3MtYU1SN1U2ZGFpNQ?oc=5", "source_name": "TipRanks", "published_at": "2026-07-15T08:47:48+00:00", "published_display": "15 Jul 2026 08:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pengana Capital Group Crosses 5% Threshold in Amplia Therapeutics with 27.5 Million Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQNy1PRjNqS1JzUF9uSUdBSkdlV3ljNlhIUVp1R3FablB0N3lleUhCUng2cndMR1pmUXRLbEV2VTY1TE9hMEpCdmZSTVlUcXhNZGZ1U0tlbTJoSkNnY3JySTFXS2VoOXN1TWV6MW5Nb1NQSjBUMVIzeG8tamlxd3pHNndHbUxpU0ZZQXdoYllXV3RYRWJ2TUNjc05tWGF2cmg0VnlJcG5FTTlsekhfaGdXNlFWUDBOZnlaRDhzdlJVczlnU2xpbUlLdDl3?oc=5", "source_name": "Kalkine", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Amplia Therapeutics (ASX: ATX) Shares Rise 13% on Monday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQNkQ4MmZsaHdlbHY2dE5rM1RHSVh2VHp1cGNvRmM4dzM4WFlkVndjdm5XRUZ3dEQ5d0JSVGd6UlpyV2JhTmNKeXBDUV9VUWU5dGtpZlBNMGFhOTFpVEdXTXdWajBOeExnbmVEUExXV25weTRCM1Y3aVJDdHJVREd6Z3Fsd1NKZzlfbVl2SlhjV2E0VWoxRUJsWVFQdFV3MlhF?oc=5", "source_name": "Kalkine", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Amplia Therapeutics (ASX:ATX) Is Drawing Fresh Buzz?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNNDBuNkRBcFlGWVlMVDBUcnpra3BHdHc5bm94U1NQdDlpZ0lmdjJzeU1id1lMT0xTWVY1X1hud1ZKcWJDTWVqaXVHcnJkY2J5RWR4ZmxNSjQ2Q2ZZZjMxWnRrU3BhcUVMS3JscnRNMkVCcXU4aVFjb2tITUJYXy00UG5vR0pGWUFLa1MxamFxdGhxZjlSTVE?oc=5", "source_name": "Kalkine", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQS2hZNlZ0aE1aUndpc2RTZEIxMm5GZ0doWF8taF9ZRjVUYmJVVHBOdk1HaU1TTk9NZ2RQOHZqX2hRTElWU1h1UXpzbjJ5QjdnMWNuSVR0S0d4SHFWOEZBRzNXcHBmRS1GZjZ3QTdVTTZKZFZ1SlFCZmVWLWVEMmhrTXpkRE5sQVZxSjN4SXVGZWhlVUJFOFY5dDE2VkZBRDVzak1jZ1BVMG5LMFVqcU9fMXF5aDExVUxSYTlaSkJR?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPWnI5Vkp3MmFJVFJTTG1QVjRlWnl6Nk5qbEhNenZobGZXQVJtaHdvbHNkUFBfZXk1cldoMUkxWm5sMkt3RFE2MHlWMnlMdC1sNG1pT0VyWEU2NmtzV0Vfb0RNS0dzR0E5MnNYSHFqRFJTZjlIczRWTEZyTEFWdjJLMVBLVnRTdEpqSnZ6ZHB1YWhYRDRvSlNmWE4xbHJDNWM?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQak1YWG02YkliWVMxbFF4YmRkOVhHeDBwRUxSZHp0N0toRWppdVVfZnlfVnBlempCYzJNY2RXM1N1OXVfbjY5WHV1UDA2SENzVXp6WVBUN0dLWDNaRnpWQm5GX3ZGdjNfazJIV2hqcHZRRXRJUDJHaDJiLTZpd0dXd3BPZlh4QjZQQXpTNEtBV3hySlZ4LWYzbFlKUUVSTFZUaUJ0V283SllrdFZwVXJlLUtiR244czhBRGVRUVV2NXFHZw?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Announces Proposed Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOel91dHlYOUs0ek9ZQlJVNWV5UFpmUFFkY2JRSW5Kdi1ITTVHcHVnSW1ENGg0WVhNbkFqb0xsMTh2UGpkcnk2Y2xpSjJPQnN0RlQzS3RFS242LUFlWFpRekw1Qk12eGw1cmU1VlRHbEJfMWJpQnU4RHFXOHlzYnc2R3BPdWktWEdsZmhfNm5lZ0YtQ2ZPVlJRWl96eUh1UjE5dUtnWFdSa0MzRF9DN0gybEludTdUaENM?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX Runners of the Week: Killi, Amplia, NuEnergy and 4D Medical", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNeG5HV05JNmxFWFlvb3NwZENJNXpsRVAzUE9KNENFamtzQy1uejcyR2JxX0J4R2xDaHdPNHFXRDMwM2pjeTJoQklFNmlKYzVPYWNvUG0zOFhQYTBUYUJockJLX2M0aUplYndEOUtPTkZ3elF1YlRBZFljZDRSM29nSF9fTklraTlYSGxDZnhYUWt2YjFRR2prNHRtaEN4bUh0X0F1WFh6b3pSdkV3WG5FZXZzbXBfQkgtMmNuNURXX3g?oc=5", "source_name": "SMH.com.au", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Health Check: Amplia shares almost double on pancreatic cancer trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPR0c0aGozNFdCSkhwUGJ1M1VqQ1V6MGJ3elFUMm1PSHhOeGV1T1gxTURXTlhUZHVkU1ZIZEExcW5BYWZ1R09qaGZQMGY3aXQxTnpGcm5DTERoY3owTGJTM25GRlEyalRZeV9PYU15UEVmMWZHU05vQnpGSG0wUkZ0LTJtbkltQ1J4dzZsaUg2My1ockxuSEhCQVJzQk5qQlVmUjlxdTlodG1yRU9p?oc=5", "source_name": "Stockhead", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Amplia Therapeutics (ASX:ATX) Is in a Trading Halt: What Biotech Investors Should Know?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQN1NtOURsNlUzTzl4dzFmckRQNVZxQXRLUFRQOTRUX19zRlRaM2pJS3J2WFNOelp0ODZIV0RPalo2Z1VzV3lRcWlLUGVYal8yUmJHR3pDOUVseXJHd2REMUFpTERkbm1NSVd3d2FEVnotdHM0MVBSMDBrY05YS2VwRDFKcHJWc3RPeWxuZVpUbGFTaVc5bTVoTkNjZEJxYTR5Q3BrUmZCVUNTb2g3SThNVnBoS3IyaTBxN1JwQjJJdXNKMFU?oc=5", "source_name": "Kalkine", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insights: Amplia Therapeutics Ltd (ASX:ATX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFBYTkptN2ZxTm5QYVJMQTdxYVB5R1YzWkplUjN0WGRrMHRWQ25qRXpSRW92SmZxRUVrdkhHbFdPME5mYWZhV29DTEtma3Q3bzg2?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-10-30T15:25:09+00:00", "published_display": "30 Oct 2025 15:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amplia CEO co-recipient of 2024 Prime Minister\u2019s Prize for Innovation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQbnZnS2pVcDNJMjBUT1JxVVdrNjVFb2xOS2UzMkotaXdDZVNqQVNYNXR1aVZySzdDZmpHWmMyTEJRVVhFT1ZqelMxdjZYQlpUQTdnUHdUQXlVdms5dkpKd09oT0NJRWE3SlBZOWN6ME8zZnd1ejlQNkx4RDdNR0JqRVlkMEFjX0p6d1VpXzd6bHdLZXFWaFNGazBLZ08wNE5oZnVF?oc=5", "source_name": "Stockhead", "published_at": "2024-10-10T07:00:00+00:00", "published_display": "10 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amplia Therapeutics Ltd Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgJBVV95cUxQTFJDTWNnNVZiU1AtVDhUX1A4ZUJCMnVieEc4cG5DclV0eFBSeTFMUm1yLUZ5M000NU1EdWhkYUgyM0pkcFBRb0tHaVhzZExkTWFFSkhwWG0ybnhwdU90VUtaOWR1eHE5YThVZlNFNnlnTjE0RTRwemRyb3VIek1SbE9CX3I2QUhFNmJGemJGdldGNDB4RmxEZzQwOG81eC10OGNxU0xUYmxWLTFETGdBNUVzMGNZbXpJREUzRGRBV1pZZjRpMjNmc185MndyTzlUNjlaLUF4ZG1lbURydUt3cllWTGdaSUdPMkV4WjRpTXdIdlZnNjJsN2cwd3I4cjFQX2U2ajdlaFU1WktzYXRIb3Y5bENfTXppU0VEUTBORDRPMndkb1p2UGkzNGxMaVdOclJlN3Z5TGtSU093cFE?oc=5", "source_name": "Moomoo", "published_at": "2024-09-04T07:00:00+00:00", "published_display": "04 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Announces Pricing of Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPWEhNOElpMk54T3g5OW96MlN5ZWJidG5yLUNDdXR0Nmh6czhWQndhQTZmcHJDOVd1LWtqc0UzRHFoVW9lbHYzQ2prTHBlRGs0dlo3MjRFUmlOWU8tVlgwa25sZ25NM2pUSzNCcGN2em5sRHp3RjhxYXQ5NjhsMjNtNEFuYVZuaDZ5OHJMZnEzUHF2R3V2QUROUHBsOENFbkR1ZE5wTXBGVHVMeHVzcTJ4cFFfanpaOVdvWWJzWUVVVXRScms?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2022-11-30T08:00:00+00:00", "published_display": "30 Nov 2022 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amplia Therapeutics Ltd Share Price - ATX, RNS News, Articles, Quotes, & Charts (ASX:ATX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE55NDhkVGY2ZGl5TTJ5Zld0S1ZVS2lEUnRlcWozNFVkSC1XS1JtU3B4ZkNEX1RGZzNGY3J6UEhtWjFLRml6dUNPaUdoc3QxMmRRcEJzQl9iQzliYVlTWkk3TXdQb0VXNFN5TFlJbW9LcTBWNzhJcnR2YQ?oc=5", "source_name": "Proactive financial news", "published_at": "2021-09-16T05:28:04+00:00", "published_display": "16 Sep 2021 05:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxON2dXSk9La1FIWHU0MnQ2cjc4empUUXNEOWFRZ2RYNGRtcE8tMUdDMVRVbVR6MWxBcWw4TV9rZjRjSmFvc19Ld2tlLXh5WnhDbENNaGk5TWRGTTRCakEwQ0tDNUpwOTRsMkVMbWNMQVZndDZ5d0wwbVFPSTRRZXFBTlQxa1dtc25SRVZMS05WMjBGU1AtWnZ2dEo5VDlWZHlJMDh5dGlZcl9xOWhtQnQxTnlleTRXaUxXanJZ?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2021-07-02T07:00:00+00:00", "published_display": "02 Jul 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amplia Therapeutics Limited (ASX: ATX) - Announcements", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPOU5VZUpZc1QzNlA5TjYtSWFQd1ljRmRuMlVydzByc044ZEM3bW9IelAyZGVXZV9ZelFldlBndl9ZOWZLRVhnOEdHb3lVaWFiMFIzZnZRbzdTMkdhcEFubm1Oa3kzdG03U1M1b3VyY3VVTVdKVDZhMU1SYWJCY0FBTzJqcG1MTFBabWNhZjRIcUlqclRzX0pyajczVQ?oc=5", "source_name": "intelligentinvestor.com.au", "published_at": "2019-10-09T13:20:57+00:00", "published_display": "09 Oct 2019 13:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amplia Therapeutics Limited (ASX:ATX) - Shares, Dividends & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQci1PUmpYZlR1YWw0alZIZ3BNRWtXUmxHMWxPY0EzZW1JcWEtQlVUUUI4Ymw5NVlZVGJlZVNjNUpRc01wWDNjWGFKV2sySHk3cFQ3UzJESXpTWkJCNzVsVGtncFpjRjk3QlBTVVljVlliTFVaWVRnUG9uSXdvVFVBWHZTdkZLUFNZ?oc=5", "source_name": "intelligentinvestor.com.au", "published_at": "2019-09-23T16:52:35+00:00", "published_display": "23 Sep 2019 16:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Amplia Therapeutics Issues New Employee Incentive Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOdkMwY1Jva1hpVHZuTGlJZjhxemg1SkpvazhpWWpNei0yVHl2V09GMzFJUVEyNVBIVFZiQ2VoMV91MHhrclNHTTBTdkhmczBlaGNtbnhWclRNdWVOS3A2bzJ6eS1NX3J0ZGxtR0hxa3gzQW9SbDFyU3lSWFdZUFNmSWlvR04wNkJtSTJqNzgtU2d1YkNibTlSbnNUeGVEc0kyVFBhS3MtYU1SN1U2ZGFpNQ?oc=5", "source_name": "TipRanks", "published_at": "2026-07-15T08:47:48+00:00", "published_display": "15 Jul 2026 08:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pengana Capital Group Crosses 5% Threshold in Amplia Therapeutics with 27.5 Million Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQNy1PRjNqS1JzUF9uSUdBSkdlV3ljNlhIUVp1R3FablB0N3lleUhCUng2cndMR1pmUXRLbEV2VTY1TE9hMEpCdmZSTVlUcXhNZGZ1U0tlbTJoSkNnY3JySTFXS2VoOXN1TWV6MW5Nb1NQSjBUMVIzeG8tamlxd3pHNndHbUxpU0ZZQXdoYllXV3RYRWJ2TUNjc05tWGF2cmg0VnlJcG5FTTlsekhfaGdXNlFWUDBOZnlaRDhzdlJVczlnU2xpbUlLdDl3?oc=5", "source_name": "Kalkine", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Amplia Therapeutics (ASX: ATX) Shares Rise 13% on Monday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQNkQ4MmZsaHdlbHY2dE5rM1RHSVh2VHp1cGNvRmM4dzM4WFlkVndjdm5XRUZ3dEQ5d0JSVGd6UlpyV2JhTmNKeXBDUV9VUWU5dGtpZlBNMGFhOTFpVEdXTXdWajBOeExnbmVEUExXV25weTRCM1Y3aVJDdHJVREd6Z3Fsd1NKZzlfbVl2SlhjV2E0VWoxRUJsWVFQdFV3MlhF?oc=5", "source_name": "Kalkine", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Amplia Therapeutics (ASX:ATX) Is Drawing Fresh Buzz?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNNDBuNkRBcFlGWVlMVDBUcnpra3BHdHc5bm94U1NQdDlpZ0lmdjJzeU1id1lMT0xTWVY1X1hud1ZKcWJDTWVqaXVHcnJkY2J5RWR4ZmxNSjQ2Q2ZZZjMxWnRrU3BhcUVMS3JscnRNMkVCcXU4aVFjb2tITUJYXy00UG5vR0pGWUFLa1MxamFxdGhxZjlSTVE?oc=5", "source_name": "Kalkine", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQS2hZNlZ0aE1aUndpc2RTZEIxMm5GZ0doWF8taF9ZRjVUYmJVVHBOdk1HaU1TTk9NZ2RQOHZqX2hRTElWU1h1UXpzbjJ5QjdnMWNuSVR0S0d4SHFWOEZBRzNXcHBmRS1GZjZ3QTdVTTZKZFZ1SlFCZmVWLWVEMmhrTXpkRE5sQVZxSjN4SXVGZWhlVUJFOFY5dDE2VkZBRDVzak1jZ1BVMG5LMFVqcU9fMXF5aDExVUxSYTlaSkJR?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPWnI5Vkp3MmFJVFJTTG1QVjRlWnl6Nk5qbEhNenZobGZXQVJtaHdvbHNkUFBfZXk1cldoMUkxWm5sMkt3RFE2MHlWMnlMdC1sNG1pT0VyWEU2NmtzV0Vfb0RNS0dzR0E5MnNYSHFqRFJTZjlIczRWTEZyTEFWdjJLMVBLVnRTdEpqSnZ6ZHB1YWhYRDRvSlNmWE4xbHJDNWM?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQak1YWG02YkliWVMxbFF4YmRkOVhHeDBwRUxSZHp0N0toRWppdVVfZnlfVnBlempCYzJNY2RXM1N1OXVfbjY5WHV1UDA2SENzVXp6WVBUN0dLWDNaRnpWQm5GX3ZGdjNfazJIV2hqcHZRRXRJUDJHaDJiLTZpd0dXd3BPZlh4QjZQQXpTNEtBV3hySlZ4LWYzbFlKUUVSTFZUaUJ0V283SllrdFZwVXJlLUtiR244czhBRGVRUVV2NXFHZw?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Announces Proposed Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOel91dHlYOUs0ek9ZQlJVNWV5UFpmUFFkY2JRSW5Kdi1ITTVHcHVnSW1ENGg0WVhNbkFqb0xsMTh2UGpkcnk2Y2xpSjJPQnN0RlQzS3RFS242LUFlWFpRekw1Qk12eGw1cmU1VlRHbEJfMWJpQnU4RHFXOHlzYnc2R3BPdWktWEdsZmhfNm5lZ0YtQ2ZPVlJRWl96eUh1UjE5dUtnWFdSa0MzRF9DN0gybEludTdUaENM?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX Runners of the Week: Killi, Amplia, NuEnergy and 4D Medical", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNeG5HV05JNmxFWFlvb3NwZENJNXpsRVAzUE9KNENFamtzQy1uejcyR2JxX0J4R2xDaHdPNHFXRDMwM2pjeTJoQklFNmlKYzVPYWNvUG0zOFhQYTBUYUJockJLX2M0aUplYndEOUtPTkZ3elF1YlRBZFljZDRSM29nSF9fTklraTlYSGxDZnhYUWt2YjFRR2prNHRtaEN4bUh0X0F1WFh6b3pSdkV3WG5FZXZzbXBfQkgtMmNuNURXX3g?oc=5", "source_name": "SMH.com.au", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Health Check: Amplia shares almost double on pancreatic cancer trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPR0c0aGozNFdCSkhwUGJ1M1VqQ1V6MGJ3elFUMm1PSHhOeGV1T1gxTURXTlhUZHVkU1ZIZEExcW5BYWZ1R09qaGZQMGY3aXQxTnpGcm5DTERoY3owTGJTM25GRlEyalRZeV9PYU15UEVmMWZHU05vQnpGSG0wUkZ0LTJtbkltQ1J4dzZsaUg2My1ockxuSEhCQVJzQk5qQlVmUjlxdTlodG1yRU9p?oc=5", "source_name": "Stockhead", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Amplia Therapeutics (ASX:ATX) Is in a Trading Halt: What Biotech Investors Should Know?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQN1NtOURsNlUzTzl4dzFmckRQNVZxQXRLUFRQOTRUX19zRlRaM2pJS3J2WFNOelp0ODZIV0RPalo2Z1VzV3lRcWlLUGVYal8yUmJHR3pDOUVseXJHd2REMUFpTERkbm1NSVd3d2FEVnotdHM0MVBSMDBrY05YS2VwRDFKcHJWc3RPeWxuZVpUbGFTaVc5bTVoTkNjZEJxYTR5Q3BrUmZCVUNTb2g3SThNVnBoS3IyaTBxN1JwQjJJdXNKMFU?oc=5", "source_name": "Kalkine", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insights: Amplia Therapeutics Ltd (ASX:ATX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFBYTkptN2ZxTm5QYVJMQTdxYVB5R1YzWkplUjN0WGRrMHRWQ25qRXpSRW92SmZxRUVrdkhHbFdPME5mYWZhV29DTEtma3Q3bzg2?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-10-30T15:25:09+00:00", "published_display": "30 Oct 2025 15:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amplia CEO co-recipient of 2024 Prime Minister\u2019s Prize for Innovation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQbnZnS2pVcDNJMjBUT1JxVVdrNjVFb2xOS2UzMkotaXdDZVNqQVNYNXR1aVZySzdDZmpHWmMyTEJRVVhFT1ZqelMxdjZYQlpUQTdnUHdUQXlVdms5dkpKd09oT0NJRWE3SlBZOWN6ME8zZnd1ejlQNkx4RDdNR0JqRVlkMEFjX0p6d1VpXzd6bHdLZXFWaFNGazBLZ08wNE5oZnVF?oc=5", "source_name": "Stockhead", "published_at": "2024-10-10T07:00:00+00:00", "published_display": "10 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amplia Therapeutics Ltd Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgJBVV95cUxQTFJDTWNnNVZiU1AtVDhUX1A4ZUJCMnVieEc4cG5DclV0eFBSeTFMUm1yLUZ5M000NU1EdWhkYUgyM0pkcFBRb0tHaVhzZExkTWFFSkhwWG0ybnhwdU90VUtaOWR1eHE5YThVZlNFNnlnTjE0RTRwemRyb3VIek1SbE9CX3I2QUhFNmJGemJGdldGNDB4RmxEZzQwOG81eC10OGNxU0xUYmxWLTFETGdBNUVzMGNZbXpJREUzRGRBV1pZZjRpMjNmc185MndyTzlUNjlaLUF4ZG1lbURydUt3cllWTGdaSUdPMkV4WjRpTXdIdlZnNjJsN2cwd3I4cjFQX2U2ajdlaFU1WktzYXRIb3Y5bENfTXppU0VEUTBORDRPMndkb1p2UGkzNGxMaVdOclJlN3Z5TGtSU093cFE?oc=5", "source_name": "Moomoo", "published_at": "2024-09-04T07:00:00+00:00", "published_display": "04 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Announces Pricing of Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPWEhNOElpMk54T3g5OW96MlN5ZWJidG5yLUNDdXR0Nmh6czhWQndhQTZmcHJDOVd1LWtqc0UzRHFoVW9lbHYzQ2prTHBlRGs0dlo3MjRFUmlOWU8tVlgwa25sZ25NM2pUSzNCcGN2em5sRHp3RjhxYXQ5NjhsMjNtNEFuYVZuaDZ5OHJMZnEzUHF2R3V2QUROUHBsOENFbkR1ZE5wTXBGVHVMeHVzcTJ4cFFfanpaOVdvWWJzWUVVVXRScms?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2022-11-30T08:00:00+00:00", "published_display": "30 Nov 2022 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amplia Therapeutics Ltd Share Price - ATX, RNS News, Articles, Quotes, & Charts (ASX:ATX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE55NDhkVGY2ZGl5TTJ5Zld0S1ZVS2lEUnRlcWozNFVkSC1XS1JtU3B4ZkNEX1RGZzNGY3J6UEhtWjFLRml6dUNPaUdoc3QxMmRRcEJzQl9iQzliYVlTWkk3TXdQb0VXNFN5TFlJbW9LcTBWNzhJcnR2YQ?oc=5", "source_name": "Proactive financial news", "published_at": "2021-09-16T05:28:04+00:00", "published_display": "16 Sep 2021 05:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxON2dXSk9La1FIWHU0MnQ2cjc4empUUXNEOWFRZ2RYNGRtcE8tMUdDMVRVbVR6MWxBcWw4TV9rZjRjSmFvc19Ld2tlLXh5WnhDbENNaGk5TWRGTTRCakEwQ0tDNUpwOTRsMkVMbWNMQVZndDZ5d0wwbVFPSTRRZXFBTlQxa1dtc25SRVZMS05WMjBGU1AtWnZ2dEo5VDlWZHlJMDh5dGlZcl9xOWhtQnQxTnlleTRXaUxXanJZ?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2021-07-02T07:00:00+00:00", "published_display": "02 Jul 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amplia Therapeutics Limited (ASX: ATX) - Announcements", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPOU5VZUpZc1QzNlA5TjYtSWFQd1ljRmRuMlVydzByc044ZEM3bW9IelAyZGVXZV9ZelFldlBndl9ZOWZLRVhnOEdHb3lVaWFiMFIzZnZRbzdTMkdhcEFubm1Oa3kzdG03U1M1b3VyY3VVTVdKVDZhMU1SYWJCY0FBTzJqcG1MTFBabWNhZjRIcUlqclRzX0pyajczVQ?oc=5", "source_name": "intelligentinvestor.com.au", "published_at": "2019-10-09T13:20:57+00:00", "published_display": "09 Oct 2019 13:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amplia Therapeutics Limited (ASX:ATX) - Shares, Dividends & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQci1PUmpYZlR1YWw0alZIZ3BNRWtXUmxHMWxPY0EzZW1JcWEtQlVUUUI4Ymw5NVlZVGJlZVNjNUpRc01wWDNjWGFKV2sySHk3cFQ3UzJESXpTWkJCNzVsVGtncFpjRjk3QlBTVVljVlliTFVaWVRnUG9uSXdvVFVBWHZTdkZLUFNZ?oc=5", "source_name": "intelligentinvestor.com.au", "published_at": "2019-09-23T16:52:35+00:00", "published_display": "23 Sep 2019 16:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 85, "total_relevant": 20, "sentiment_summary": {"positive": 2, "negative": 0, "neutral": 18, "score": 51, "total": 20, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 92, "events": [{"event": "general", "label": "Market update", "weight": 9.9, "count": 18}, {"event": "earnings", "label": "Earnings", "weight": 1.1, "count": 2}], "positive_events": 2, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 0.14, "latest_week": "2026-07-10", "one_week_move": -3.3, "four_week_move": 31.8, "twelve_week_move": -12.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.616332, "market_dynamics_buy_signal": false, "relative_strength": -5.512692, "fair_value_gap": 30.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 36.9263, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.3% over one week, +31.8% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Intellia Therapeutics", "count": 5}, {"label": "Kalkine", "count": 4}, {"label": "Stockhead", "count": 2}, {"label": "intelligentinvestor.com.au", "count": 2}, {"label": "TipRanks", "count": 1}, {"label": "Market source", "count": 1}, {"label": "simplywall.st", "count": 1}, {"label": "SMH.com.au", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 20}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 18}, {"label": "Earnings", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "92/100 classification confidence."}, {"label": "Company focus", "value": "20", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.3% over one week, +31.8% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Amplia Therapeutics Issues New Employee Incentive Options"}], "updated_at": "2026-07-17T03:40:36.661865+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}